On 9 July 2025, Alvotech announced that it has acquired Switzerland-headquartered Ivers Lee Group to expand its capacity for assembly and packaging and support its growth plans. According to Alvotech, the acquisition of Ivers Lee will provide “added flexibility and capacity to meet increased global demand” for Alvotech’s biosimilars, including the planned launch of three biosimilars in 2025.
This follows the June 2025 completion of Alvotech’s acquisition of Xbrane’s Swedish R&D operations and biosimilar to UCB’s Cimzia® (certolizumab pegol) in a US$28.9m deal.
Alvotech has also recently entered into a number of commercialisation agreements, including with Advanz Pharma in Europe in relation to AVT10, biosimilar to UCB’s Cimzia® (certolizumab pegol) (in July 2025) and canakinumab and ofatumumab biosimilars (in May 2025); and with Dr Reddy’s for the global development, manufacturing and commercialisation of a biosimilar to MSD’s Keytruda® (pembrolizumab) (in June 2025).
Alvotech’s AVT06, biosimilar to Bayer/Regeneron’s Eylea® (aflibercept, 2mg), received a positive CHMP opinion in June 2025 (it is to be commercialised in the EU by Advanz) and is expected to obtain US approval in Q4 2025 (Alvotech/Teva’s BLA having been accepted by the FDA in February 2025). Alvotech/Teva’s Selarsdi® was the second biosimilar to J&J/Janssen’s Stelara® (ustekinumab) launched in the US in February 2025.